2-(4-diphenylmethylpiperazin-1-yl)ethylphthalimide | 101619-98-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-diphenylmethylpiperazin-1-yl)ethylphthalimide
• 英文别名: 2-[2-(4-Benzhydrylpiperazin-1-yl)ethyl]isoindole-1,3-dione
• CAS: 101619-98-1
• 化学式: C₂₇H₂₇N₃O₂
• 分子量: 425.53
• InChiKey: HCKXQDKUSXMTRX-UHFFFAOYSA-N

物化性质

• 沸点：
  569.9±50.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  43.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-diphenylmethylpiperazin-1-yl)ethylphthalimide 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-(4-benzhydrylpiperazin-1-yl)ethan-1-amine
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. I. Synthesis and structure-activity relationships of N-((4-substituted 1-piperazinyl)alkyl)-3-(aryl and heteroaryl)acrylamides.

  摘要：

  一系列新的丙烯酰胺衍生物（7-10）被合成。对这些化合物的抗过敏活性进行了评估，并考察了它们的结构-活性关系。化合物10d，即N[4-(4-二苯甲基-1-哌嗪基)丁基]3-(3-吡啶基)丙烯酰胺，在口服给药的大鼠被动皮肤过敏反应（PCA）测试中显示出与酮替芬相当或更优越的抗过敏活性。与酮替芬不同，10d在体外对5-脂氧合酶的抑制活性比咖啡酸更强，而其体外抗组胺活性则弱于酮替芬。此外，它对大鼠肥大细胞释放组胺的抑制活性约为色甘酸二钠（DSCG）的三分之二。化合物10d是一种有前途的多种过敏性疾病治疗药物。

  DOI：

  10.1248/cpb.37.100
• 作为产物：
  描述：

  N-(2-溴乙基)邻苯二甲酰亚胺 、 二苯甲基哌嗪 在 potassium carbonate 、 sodium iodide 作用下， 以 丁酮 为溶剂， 反应 4.5h， 生成 2-(4-diphenylmethylpiperazin-1-yl)ethylphthalimide
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. I. Synthesis and structure-activity relationships of N-((4-substituted 1-piperazinyl)alkyl)-3-(aryl and heteroaryl)acrylamides.

  摘要：

  一系列新的丙烯酰胺衍生物（7-10）被合成。对这些化合物的抗过敏活性进行了评估，并考察了它们的结构-活性关系。化合物10d，即N[4-(4-二苯甲基-1-哌嗪基)丁基]3-(3-吡啶基)丙烯酰胺，在口服给药的大鼠被动皮肤过敏反应（PCA）测试中显示出与酮替芬相当或更优越的抗过敏活性。与酮替芬不同，10d在体外对5-脂氧合酶的抑制活性比咖啡酸更强，而其体外抗组胺活性则弱于酮替芬。此外，它对大鼠肥大细胞释放组胺的抑制活性约为色甘酸二钠（DSCG）的三分之二。化合物10d是一种有前途的多种过敏性疾病治疗药物。

  DOI：

  10.1248/cpb.37.100

文献信息

• Hydantoin derivatives for treating complications of diabetes and
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd.

  公开号：US05164391A1

  公开（公告）日：1992-11-17

  The invention relates to a hydantoin derivative, salt thereof, process for the preparation thereof, and medicine containing the derivative. The derivative is represented by the formula ##STR1## wherein M is --CONH--NHR.sup.1 group, --CONH--OR.sup.2 group, ##STR2## in which R.sup.1 is hydrogen atom, an alkyl group, an alkenyl group, a phenyl radical, a substituted phenyl group, a naphthyl radical, a substituted naphthyl group, a pyridyl radical, a furyl radical or a thienyl radical, R.sup.2 is a hydrogen atom, an alkyl group, a phenyl radical or a substituted phenyl group, R.sup.3 and R.sup.4 are the same or different independently, each being a phenyl radical, or an aralkyl group, or R.sup.3 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.4 and a possible nitrogen or oxygen atom, R.sup.5 forms a substituted or non-substituted saturated heterocyclic ring together with R.sup.6 and a possible nitrogen or oxygen atom, R.sup.7 is a nitroxy radical or a heteroaryl group, .sub.m and .sub.n are an integer of 2 to 5, Q is a hydrogen atom or ##STR3## in which R.sup.8 and R.sup.9 are the same or different independently, each being a substituted or non-substituted alkyl group, or R.sup.8 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.9 and a possible nitrogen or oxygen atom, .sub.r is an integer of 2 to 5, T and X are the same or different independently, each being a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or an alkylmercapto group, and Z is an oxygen or sulfur atom. The derivatives and salts thereof are useful for the treatment of complications of diabetes and circulatory diseases.

  该发明涉及一种咪唑烷酮衍生物及其盐，其制备方法以及含有该衍生物的药物。该衍生物由以下结构表示：其中 M 是--CONH--NHR.sup.1基团，--CONH--OR.sup.2基团，R.sup.1 是氢原子，烷基，烯基，苯基，取代苯基，萘基，取代萘基，吡啶基，呋喃基或噻吩基，R.sup.2 是氢原子，烷基，苯基或取代苯基，R.sup.3 和 R.sup.4 独立相同或不同，各自是苯基或芳基烷基，或 R.sup.3 可与 R.sup.4 一起形成取代或非取代的C.sub.5-6饱和杂环环，其中可能包括一个氮原子或氧原子，R.sup.5 与 R.sup.6 一起形成取代或非取代的饱和杂环环，其中可能包括一个氮原子或氧原子，R.sup.7 是亚硝基基团或杂芳基团，m 和 n 是2到5的整数，Q 是氢原子或##STR3##，其中 R.sup.8 和 R.sup.9 独立相同或不同，各自是取代或非取代的烷基，或 R.sup.8 可与 R.sup.9 一起形成取代或非取代的C.sub.5-6饱和杂环环，其中可能包括一个氮原子或氧原子，r 是2到5的整数，T 和 X 独立相同或不同，各自是氢原子，卤原子，烷基，烷氧基或烷巯基，Z 是氧原子或硫原子。这些衍生物及其盐对于治疗糖尿病和循环疾病的并发症是有用的。
• Hydantoin derivatives for treating complications of diabetes and circulatory diseases
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：EP0418834A1

  公开（公告）日：1991-03-27

  The invention relates to a hydantoin derivative, salt thereof, process for the preparation thereof, and medicine containing the derivative. The derivative is represented by the formula wherein M is -CONH-NHR' group, -CONH-OR2 group, or -CONH(CH2)nR7 group, in which R1 is hydrogen atom, an alkyl group, an alkenyl group, a phenyl radical, a substituted phenyl group, a naphtyl radical, a substituted naphtyl group, a pyridyl radical, a furyl radical or a thienyl radical, R2 is a hydrogen atom, an alkyl group, a phenyl radical or a substituted phenyl group, R3 and R4 are same or different independently, each being a hydrogen atom, an alkyl group, a phenyl radical, a substituted phenyl group or an aralkyl group, or R3 may form a substituted or non-substituted C5-6 saturated heterocyclic ring together with R4 and a possible nitrogen or oxygen atom, R5 forms a substituted or non-substituted saturated heterocyclic ring together with R6 and a possible nitrogen or oxygen atom, R7 is a nitroxy radical or a heteroaryl group, m and n are an integer of 2 to 5, Q is a hydrogen atom or in which R8 and R9 are same or different independently, each being a substituted or non-substituted alkyl group, or R8 may form a substituted or non-substituted Cs-6 saturated heterocyclic ring together with R9 and a possible nitrogen or oxygen atom, is an integer of 2 to 5, T and X are same or different independently, each being a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or an alkylmercapto group, and Z is an oxygen or sulfur atom. The derivatives and salts thereof are useful for the treatment of complications of diabetes and circulatory diseases.

  本发明涉及一种海因衍生物、其盐、其制备工艺以及含有该衍生物的药物。该衍生物由式表示 其中 M 为-CONH-NHR'基团、-CONH-OR2 基团、 或-CONH(CH2)nR7 基团，其中 R1 是氢原子、烷基、烯基、苯基、取代苯基、萘基、取代萘基、吡啶基、呋喃基或噻吩基，R2 是氢原子、烷基、苯基或取代苯基，R3 和 R4 独立地相同或不同，各自是氢原子、烷基、苯基或取代苯基、或 R3 可与 R4 和一个可能的氮原子或氧原子一起形成一个取代或非取代的 C5-6 饱和杂环，R5 与 R6 和一个可能的氮原子或氧原子一起形成一个取代或非取代的饱和杂环，R7 是硝酸基或杂芳基，m 和 n 是 2 至 5 的整数，Q 是氢原子，或 其中 R8 和 R9 独立地相同或不同，各自为取代或非取代的烷基，或 R8 可与 R9 和可能的氮原子或氧原子一起形成取代或非取代的 Cs-6 饱和杂环，为 2 至 5 的整数，T 和 X 独立地相同或不同，各自为氢原子、卤素原子、烷基、烷氧基或烷基巯基，Z 为氧原子或硫原子。这些衍生物及其盐类可用于治疗糖尿病并发症和循环系统疾病。
• Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers
  作者：Jie Eun Lee、Hun Yeong Koh、Seon Hee Seo、Yi Yeon Baek、Hyewhon Rhim、Yong Seo Cho、Hyunah Choo、Ae Nim Pae

  DOI：10.1016/j.bmcl.2010.05.030

  日期：2010.7

  T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pain. In this study, as a part of our ongoing efforts to develop potent T-type calcium channel blockers, we designed oxazole derivatives substituted with arylpiperazinylalkylamines. The oxazoles were synthesized in a convenient convergent synthetic method, and biologically evaluated against alpha(1G) (Ca(V)3.1) T-type calcium channel. Among total 41 oxazole compounds synthesized, the most active one was the compound 10-35 with an IC(50) value of 0.65 mu M, which is comparable with that of mibefradil. (C) 2010 Elsevier Ltd. All rights reserved.
• NISHIKAWA, YOSHINORI;SHINDO, TOKUHIKO;ISHII, KATSUMI;NAKAMURA, HIDEO;KON,+, CHEM. AND PHARM. BULL., 37,(1989) N, C. 100-105
  作者：NISHIKAWA, YOSHINORI、SHINDO, TOKUHIKO、ISHII, KATSUMI、NAKAMURA, HIDEO、KON,+

  DOI：——

  日期：——
• US5164391A
  申请人：——

  公开号：US5164391A

  公开（公告）日：1992-11-17